Short Title: VEE complex, MADV and EEEV rRT-PCR

- 3 Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga and Eastern
- 4 equine encephalitis viruses: application in clinical diagnostic and mosquito surveillance
- 6 Jean-Paul Carrera^{1,2,3#}, Dimelza Araúz², Alejandra Rojas⁴, Fátima Cardozo⁴, Victoria Stittleburg⁵,
- Josefrancisco Galue^{2,3}, Carlos Lezcano-Coba^{2,3}, Nikos Vasilakis^{6,7,8,9,10,11}, Juan Miguel Pascale¹²
- 8 Anayansi Valderrama¹³, Christl A. Donnelly^{14,15}, Nuno R. Faria^{15,16}, Jesse J. Waggoner^{5,17,#}
- 10 1 Department of Zoology, University of Oxford, Oxford, United Kingdom
- 2 Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health
- 12 Studies, Panama City, Panama
- 13 3 Viral Emerging Disease Dynamics group, Gorgas Memorial Institute of Health Studies,
- 14 Panama City, Panama
- 4 Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
- 16 Departamento de Producción, Paraguay
- 17 5 Emory University, Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia,
- 18 USA

1

2

5

9

- 19 6 Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA.
- 20 7 Department of Preventive Medicine and Population Health, The University of Texas Medical
- 21 Branch, Galveston, Texas, USA.
- 22 8 Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical
- 23 Branch, Galveston, Texas, USA.
- 24 9 Center for Vector-Borne and Zoonotic Diseases, The University of Texas Medical Branch,
- 25 Galveston, Texas, USA.
- 26 10 Center for Tropical Diseases, The University of Texas Medical Branch, Galveston, Texas,
- 27 USA.
- 28 11 Institute for Human Infection and Immunity, The University of Texas Medical Branch,
- 29 Galveston, Texas, USA.
- 30 12 Clinical of Tropical Diseases and Research Unit, Gorgas Memorial Institute of Health
- 31 Studies, Panama City, Panama
- 32 13 Department of Medical Entomology, Gorgas Memorial Institute of Health Studies, Panama
- 33 City, Panama
- 34 14 Department of Statistics, University of Oxford, Oxford, United Kingdom
- 35 15 MRC Centro for Global Infectious Disease Analysis (MRC-GIDA), Department of Infectious
- 36 Disease Epidemiology, Imperial College London, London United Kingdom
- 37 16 Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São
- 38 Paulo, Brazil

40

39 17 Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA

41 #Address correspondence to: Jean-Paul Carrera, Peter Medawar Building for Pathogen Research, Oxford, UK, OX1 3SY. Email: jean.carrera@zoo.ox.ac.uk or Jesse J. Waggoner, 1760 Haygood 42 43 Drive NE, Room E-169, Bay E-1, Atlanta, GA, USA, 30322. Email: jjwaggo@emory.edu; 44 Telephone: +1 (404) 712-2360. 45 46 Word Count: Abstract, 223; Manuscript, 3358 47 Inserts: Tables 3, Figure 1 48 49 **Abstract** 50 **Background.** Venezuelan equine encephalitis (VEE) complex, eastern equine encephalitis virus 51 (EEEV), and Maradiaga virus (MADV), are associated with severe neurological disease in 52 human and equine hosts. We aimed to overcome the lack of available molecular diagnostics for 53 these pathogens by designing and clinically evaluating real-time reverse transcription PCRs 54 (rRT-PCRs) for 1) VEE complex and 2) MADV/EEEV. 55 Methodology/Principal Findings. Primers and probes were designed from alignments of all 56 publicly available complete genome sequences for VEE complex, EEEV and MADV. Linear 57 range for the VEE complex and MADV/EEEV rRT-PCRs extended from 2.0 to 8.0 log₁₀ 58 copies/µL with exclusive detection of the respective viruses. Fifteen serum samples from febrile 59 patients collected from 2015 and 2017 outbreaks in Panama were tested to evaluate the new 60 assays. Ten samples (66.7%) samples were positive for VEEV, and in one of these ten samples, 61 rRT-PCR detected both VEEV and MADV. The remaining five samples were negative for both 62 MADV and VEEV. Three acute samples (≤ 3 days since onset) with coincidental anti-VEEV IgM and IgG antibodies were also found positive for VEEV viral RNA. Of 150 mosquito pools, 63 3 tested positive for VEEV by rRT-PCR. Two of these yielded VEEV isolates. 64

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Conclusions. The VEE complex and MADV/EEEV rRT-PCRs provide accurate detection while yielding significant benefits over currently available molecular methods. Outcomes from the clinical evaluation provide further evidence for VEE complex and MADV co-infections and suggest that re-infection with VEE complex viruses is possible. Keywords: Venezuelan equine encephalitis, Madariaga virus, Easter equine encephalitis virus, alphavirus, rRT-PCR **Author Summary** The alphavirus encephalitis viruses include species of the Venezuelan equine encephalitis (VEE) complex, Maradiaga virus (MADV), and Eastern equine encephalitis virus (EEEV). They persist in sylvatic-enzootic cycles throughout the Americas and are transmitted to humans by *Culex* spp. mosquitoes. Human and equine outbreaks are reported sporadically in endemic regions. Detection of VEE complex, MADV and EEEV infections in the acute phase is complicated by their non-specific clinical manifestations and lack of widely available diagnostic tools. Current molecular tests lack optimal performance metrics characteristics necessary for routine diagnostic testing. Here we design two real-time RT-PCRs for VEE complex and MADV/EEEV, which were then evaluated by testing a set of clinical and mosquito samples collected during two outbreaks of VEEV and MADV in Panamá. The VEE complex and MADV/EEEV rRT-PCRs provide accurate detection while yielding significant benefits over currently available molecular methods.

Introduction

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

The new world encephalitis alphaviruses (Togaviridae, genus Alphaviridae) that comprise the Venezuelan equine encephalitis complex (VEE complex), Madariaga virus (MADV), and eastern equine encephalitis virus (EEEV) are single-stranded RNA viruses with genomes of approximately 11.7 kb, encoding four non-structural proteins (nsP1 to nsP4) and five structural proteins (capsid, E1, E2, E3 and 6K) [1,2]. These alphaviruses persist in sylvatic-enzootic cycles throughout the Americas and are transmitted to humans by *Culex* spp. mosquitoes [2,3]. VEEV, MADV and EEEV all have the potential to cause human infection, and certain VEE complex virus (VEEV) subtypes have been associated with large epizootic outbreaks involving equids and humans (VEEV subtypes IA/B and IC). Most infections in humans are asymptomatic or subclinical, however patients may develop an acute febrile illness with headache, myalgias, arthralgias, nausea and vomiting [2,4–6], which may progress to severe disease including encephalitis and the development of long-term neurologic sequelae [1,2,6]. Serologic evidence of transmission and acute symptomatic cases have been identified throughout tropical regions of Central and South America, indicating that VEE complex viruses may be relatively common but remain largely underdiagnosed[1]. MADV, previously classified as South American EEEV, is an emerging viral infection that was first identified in 2010 in the Darién province of Panamá, where VEEV subtype ID has also been detected [1–3,6]. Before the 2010 outbreak in Panama, MADV was mostly associated with equine disease and only a few human cases had been detected in Trinidad and Tobago and Brazil[7]. This contrasts with the epidemiological profile of North American EEEV, which is associated with severe and fatal human cases [8]. Diagnostic tools are not widely available for MADV, and its prevalence

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

outside of Darién in Panama remains poorly characterized. A geographic expansion of the Panamanian MADV strain into Haiti has been reported recently, highlighting the potential of MADV cases to invade new areas [9]. Detection of VEE complex, MADV and EEEV infections in the acute phase is complicated by their non-specific clinical manifestations and lack of widely available diagnostic tools. Antigenbased methods are unavailable, and although serology can confirm the diagnosis, this requires paired acute and convalescent samples [2]. Current molecular tests lack optimal performance metrics characteristics necessary for routine diagnostic testing [10–16]. Molecular assay designs have been complicated by the genetic variability of the VEE complex viruses, which comprise of at least 14 different viral subtypes[1]. VEEV infections are often misdiagnosed as dengue virus, due to overlapping clinical symptoms during the acute phase[1], and the recent identification of MADV as a unique species and human pathogen also complicates the clinical diagnosis of both etiologies[8]. Common molecular tests for VEE complex viruses employ pan-alphavirus primers to amplify a 400-500bp region of the genome with subsequent identification of the viral complex or species by sequencing or nested PCR [2,10,11,13,15–17]. Such methods are laborious and increase opportunities for laboratory contamination. In addition, pan-alphavirus primers and conventional reverse transcription-polymerase chain reaction (RT-PCR) chemistry may be less sensitive than real-time RT-PCR (rRT-PCR). However, few rRT-PCR methods have been reported in the literature to date to detect and differentiate VEEV and MADV[18]. The primary objective of the current study was to design rRT-PCRs for the VEE complex and MADV. As a secondary objective, a duplex MADV/EEEV rRT-PCR was developed to

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

differentiate these two pathogens. The two assays, for VEE complex and MADV/EEEV, were then evaluated by testing a set of clinical samples from an outbreak of VEEV and MADV in Panamá. **Materials and Methods Ethics statement** The use of human samples was approved by the Panamanian Ministry of Health (protocol number 2077), Gorgas's IRB (protocol: 335/CBI/ICGES/21), Emory University IRB (IRB00097089), and the Ethics Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (P06/2017). **Study site and field methods** Acute human samples used in the protocol validation were collected in communities of Darien, the most eastern province in Panama, during two alphavirus outbreaks in 2015 and 2017. These communities include Metetí, Cemaco, Tucutí, Yaviza, Nicanor, La Palma and El Real de Santa María (Figure 1). The Darien province borders Colombia and encompasses the Darien Gap, and the Darien National Park, a UNESCO-designated World Heritage Site [19]. For mosquito collections, a forested section of 100 x 100 meters within El Real de Santa María was selected for this study. Acute human febrile cases were identified during the 2015 our outbreak response team during the active surveillance in El Real de Santa María, this was the main selection criteria for mosquito collection. In addition, previous Alphavirus encephalitis outbreaks are frequently reported in El Real de Santa María[2,20].

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

Patient recruitment Febrile patients were identified during an enhanced surveillance program, by our outbreak response team using house-by-house visits during the 2015 and 2017 outbreaks. Blood samples were drawn from patients that met the case definition during the outbreak investigation. The case definition of a suspected case included fever and headache, while a probable case was defined as a suspected case plus somnolence, lethargy or convulsions. Blood samples were centrifuged in the field to obtain the serum, which was stored in liquid nitrogen for transportation to the Gorgas Memorial Institute of Health Studies. **Mosquito collection** Mosquito collections with CDC light traps were undertaken in the township of El Real de Santa María during an alphavirus outbreak response in 2015. Collections performed over a period of 12 hours, from 6:00 pm to 6:00 am at height of 1.5 m above ground level. Traps (BioQuip Products, Rancho Dominguez, CA) were baited with octanol and CO₂ for encephalitis vector survey. The following day, mosquitoes were collected in the field and transported to the base camp where they were anesthetized, identified to the species level using taxonomic keys[21] and placed in cryovials for storage in liquid nitrogen. Mosquitos were grouped at the species level and a maximum 20 individuals were used to produce mosquito pools for rRT-PCR, serology and isolation. Alphavirus serology All human serum samples were tested in duplicate for IgM antibodies to MADV and VEEV

antigen using an enzyme-linked immunosorbent assays (ELISA), and confirmed by a plaque-

reduction neutralization test (PRNT). For the ELISA, sucrose-acetone antigens were prepared from EEEV- (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in August 1989) and VEEV- (strain 78V-3531) infected mouse brain. For the PRNT, we used chimeric Sindbis virus SINV/MADV (derived from Brazilian MADV strain BeAn436087 and shown to be an accurate surrogate for MADV in these assays [22] and TC83, an attenuated vaccine strain of VEEV closely related to subtype ID strains that circulate in Panama [23]. The neutralizing antibody titer was determined as the reciprocal of the highest dilution that reduced plaque count by 80% (PRNT₈₀).

Viral isolation

Mosquito pool homogenates were prepared with 20-50 mosquitos in 2 mL of minimum essential medium supplemented with penicillin and streptomycin, and 20% fetal bovine serum, homogenized using a Tissue Lyser (Qiagen, Hidden, Germany), and centrifuged at 12000 rpm for 10 mins. A total of 200 μ L of serum or mosquito homogenate was inoculated in each of two 12.5-cm² flasks of Vero cells. Samples were passaged twice and monitored for cytopathic effect (CPE).

Generic alphavirus RT-PCR

Viral RNA was extracted from human sera and mosquito pool homogenates using QIAamp RNA viral extraction kit (Qiagen, Valencia, CA). Viral RNA from mosquitos were also extracted using the Macherey-Nagel extraction kit (Düren, Germany). Sera and mosquito homogenates were tested for alphaviruses using a universal alphavirus RT-PCR described previously[16]. Amplicons generated were eluted from agarose gels, purified using the QIAquick PCR

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

purification kit (Oiagen, Valencia, CA) and sequenced directly using an Applied Biosystems (Foster City, CA) 3500 Genetic Analyzer following the manufacturer's protocols. VEE complex, EEEV and MADV rRT-PCR design Separate alignments were prepared for the VEE complex, EEEV and MADV using all publicly available complete genome sequences from the NCBI Nucleotide database[24] and aligned with MegAlign software (DNASTAR, Madison, WI). The VEE complex alignment included all complete genomes from the following viruses: Cabassou, Everglades, Mosso das Pedras, Mucambo, Pixuna, Rio Negro, Tonate, and Venezuelan equine encephalitis. The VEE complex alignments were made in 2016 (n=121 sequences) and a similar alignment for MADV was made in 2019 (n=32). Primers and probes were designed with Primer3 software (primer3.ut.ee) such that each oligonucleotide contained ≤ 1 degenerate base and matched $\geq 95\%$ of available sequences for a given virus. In silico primer/probe specificity was checked by aligning sequences in BLAST (blast.ncbi.nlm.nih.gov) against (1) all available sequences and (2) only alphavirus sequences while excluding the VEE complex or MADV, respectively. Due to the similarity between MADV primers and EEEV sequences, all available EEEV complete genome sequences (n=441) were aligned and separate MADV and EEEV probes were designed for an rRT-PCR duplex assay. Alignments for each virus were repeated with all sequences available in September 2021 to confirm primer and probe sequences in contemporary strains. rRT-PCR assay performance and optimization rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of nucleic acid template.

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

Analytical evaluation was performed on a Rotor-Gene O instrument (Oiagen, Germantown, MD), and the validation with serum and mosquito pool samples were performed on an ABI7500 (Thermo Fisher). Cycling conditions were consistent with previous laboratory protocols: 52 °C × 15 min, 94 °C \times 2 min, and 45 cycles of 94 °C \times 15 s, 55 °C \times 40 s (acquire in all channels), and 68 °C × 20 s (16-19). Primer and probe sets were evaluated in singleplex reactions containing 200nM of each oligonucleotide and genomic RNA or quantified ssDNA containing the target region. Primer/probe sets were selected to generate the most sensitive detection based on cycle threshold (Ct) values, with preserved specificity. Primer and probe concentrations in the final reaction were then adjusted between 100nM and 400nM to optimize assay sensitivity. Primers were obtained from Integrated DNA Technologies (IDT, Coralville, Iowa); probes were obtained from Biosearch Technologies (Hoddesdon, United Kingdom). VEEV subtype IC and EEEV genomic RNA was purchased from Vircell Microbiologists (Granada, Spain). Quantified ssDNA containing the assay target region (IDT, Coralville, Iowa) was used for all viruses to quantify analytical performance. For ssDNA synthesis, target region sequences were selected from specific strains of VEE subtype IAB (Accession number KC344505.2) and subtype IV (Pixuna virus, Accession number NC_038673.1), MADV (Accession numbers MH359233.1 and KJ469626.1), and EEEV (Accession number KX029319.1). **Analytical evaluation** The linear range of the assay was determined by testing synthesized targets from each reference strain in quadruplicate at 8.0, 6.0, 4.0, 2.0, and 1.0 \log_{10} copies/ μ L. The linear range was defined as the range of concentrations at which 1) all replicates were detected and 2) the linear regression

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

of Ct values (y, dependent variable) versus $\log_{10} \text{copies}/\mu L$ (x, independent variable) generated an $R^2 \ge 0.99$. For the VEE complex, the lower limit of 95% detection (95% LLOD) was determined by testing 10 replicates of 2-fold serial dilutions from 200 to 25 copies/µL. For MADV and EEEV, the 95% LLOD was calculated directly from the linear range. Assay exclusivity was evaluated by testing genomic RNA from the following viruses (strain in parentheses, if designated): Rift Valley fever (h85/09); Zika (MR766); dengue virus serotype 1 (Hawaii 1944), dengue virus serotype 2 (NGC), dengue virus serotype 3 (Sleman/78), and dengue virus serotype 4 (H241); Chikungunya virus (R80422); Mayaro virus (ARV 0565, INHRR 11a-10); yellow fever virus (17D and Asibi strains); West Nile virus (NAL); St. Louis encephalitis virus (GML 902612, CorAn 9275); tick-borne encephalitis virus; Japanese encephalitis virus; Semliki forest virus; Ross river virus; Getah virus; Barmah forest virus; and Una virus (20). Specificity was also evaluated by testing 56 serum samples from locations without known transmission of VEEV or MADV. These included 8 samples collected from patients in Georgia, USA, without known travel history, and 48 samples from individuals with an acute febrile illness in Asunción, Paraguay. The latter samples have been described in detail previously (21). Total nucleic acids were extracted from 200µL of serum on an EMAG instrument (bioMérieux, Durham, NC), eluted in 50µL and run in the VEE complex and MADV/EEEV rRT-PCRs. **Statistics** Linear regression fitting and linear range calculations, including R² of the best-fit line were

performed in Excel (Microsoft, Redmond, WA). Concentrations and replicates in the linear range

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

study that did not yield Ct values were not included in the linear regression analysis. Probit analyses were performed using MedCalc, v20.013 (MedCalc Software, Belgium). **Results Characteristics of the clinical samples** A total of 15 febrile patients that met the suspected case definition were used to validate the new molecular assays. Samples were collected in Panama in 2015 and 2017, between 0 to 5 days of clinical evolution (Table 1). Mosquitos A total of 1307 mosquitos belonging to 35 species and 12 genera were collected in the community of El Real de Santa Maria, Panama, during a period of five days in 2015 (Table 2). The most abundant mosquito species was Coquilletidia venezualencis at 37.5 % and Culex *Melanoconion vomerifer* at 34.4%. The remaining mosquitos collected are presented in Table 2. rRT-PCR analytical evaluation Primers and probes for the VEE complex singleplex and MADV/EEEV duplex rRT-PCRs are shown in Table 3 along with the optimized final reaction concentrations. The linear range for each assay extended from 2.0 to 8.0 log₁₀ copies/µL (Figure 2A-D). For the VEE complex assay, the linear range was evaluated with ssDNA for subtypes IAB and IV and RNA from subtype IC (2.0 to 5.0 log₁₀ copies/μL; Figure 1A-B). The 95% LLODs, expressed in copies/μL, were: VEEV subtype IAB, 120; VEE subtype IV, 110; MADV, 19; EEEV, 19. Assay exclusivity was

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

evaluated by testing genomic RNA from VEEV subtype IC, EEEV, and a set of arboviruses, including flavi-, bunya-, and alphaviruses on a single run of the VEE complex and MADV/EEEV rRT-PCRs. VEEV and EEEV only yielded signal in the respective assays for these viruses. None of the other tested viruses generated signal in either assay. In addition, none of the 56 serum samples from Georgia, USA, or Asunción, Paraguay, tested positive in either assay. Viral detection in clinical samples and mosquito pools Previously, a total of eleven (11/15) acute sera samples collected during the in 2015 and 2017 alphavirus outbreaks had tested positive using a generic alphavirus RT-PCR [16], and were confirmed latter by sequencing as VEEV-ID infections. In 2021, a second round of generic alphavirus RT-PCR using the same set of primers was run on these fifteen stored samples, and all of them tested negative. Contrastingly, using the newly designed rRT-PCR, we were able to detect 10 VEEV RNA positive samples, including two samples that had tested negative at the initial screening in 2017 (Table 1). Three of the VEEV rRT-PCR-positive samples were also anti-VEEV IgG and IgM positive, with only 0, 2, and 3 days since onset of symptoms, respectively (Table 4). One sample was rRT-PCR positive for both VEEV and MADV viruses. Of 150 mosquito pools, 3 Cx. Mel. vomerifer mosquito pools tested positive for VEEV with the rRT-PCR. Two of these rRT-PCR positive pools also yielded viral isolates. **Discussion** Over the past 40 years, various molecular assays have been developed for the detection of VEEV and VEE complex viruses [5,11–18,25]. Many involve conventional or nested RT-PCRs that

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

employ pan-alphavirus primers to amplify a large region of the genome, with subsequent species differentiation using specific nested primers, biotinylated probes, sequencing, or melt-curve analysis [11–17]. Vina-Rodriguez et al., reported an rRT-PCR that was designed from an alignment of 33 VEEV sequences [18]. Development of this assay did not include other species that comprise the VEE complex, and clinical samples were not available for evaluation [18]. Our VEE complex singleplex and MADV/EEEV duplex rRT-PCRs provide accurate detection and real-time differentiation of VEE complex, MADV and EEEV. These were designed using a greater number of complete genome sequences with confirmation in silico that the primers and probes match contemporary alignments. Using these assays, we detected VEEV and MADV in samples that had tested negative with a reference RT-PCR [16]. Interestingly, our new method has failed to detect two sample that previously tested positive back in 2015 using the alphavirus generic primers[16]. However, a second round of the generic Alphavirus RT-PCR undertaken in 2017 with same primers have also failed to reamplify the former positives. Viral RNA degradation over time is a likely explanation of these false negative samples [26]. Taken together, these data demonstrate the potential of these methods to improve VEE complex, MADV and EEEV molecular detection, even in long time storage samples. Species of the VEE complex have been detected throughout the Americas, and in certain locations, VEE complex may account for a significant proportion of non-dengue acute febrile illness (1, 5). However, it is likely that both VEE complex viruses and MADV remain underdiagnosed due to the lack of available and convenient methods for detection. VEEV subtype 1D, and MADV have been identified in Panamá, with co-circulation detected in the Darién province along the Colombian border [2,3,6]. Co-circulation and the potential for co-

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

infection with these two viruses complicate their detection, particularly when existing molecular methods cannot distinguish between these pathogens[16]. In this study, we identified an individual with a VEEV-MADV co-infection, highlighting another advantage of our VEE complex and MADV/EEEV rRT-PCRs over previous methods. Co-infection cases are epidemiologically significant and may have clinical relevance if co-infections are associated with more severe disease[2]. The similar clinical presentation of two related alphavirus, VEEV and MADV, also complicates alphavirus diagnosis and surveillance in endemic regions. Cases are often detected during the neurological phase of the disease [2,27]. At this stage, the virus has been cleared from the serum and diagnosis relies mostly on serological testing [2,27]. Because alphaviruses can induce an IgM response that lasts up to 2 to 3 months, the detection of anti-VEEV or -MADV IgM alone could yield a misdiagnosis if seroconversion is not observed [2]. Our newly developed VEE complex and MADV/EEEV rRT-PCR can be rapidly incorporated into diagnostic algorithms in endemic regions. The currently developed rRT-PCR allowed us to detect VEEV viral RNA in samples collected from patients in the first few days of symptoms, whereas alphavirus IgM and IgG antibody responses usually develop >5-7 days post symptom onset[28]. Interestingly, three patients with detectable VEE RNA were also VEEV IgM and IgG-reactive, suggesting that VEEV re-infections are possible, a finding with potential implications for alphavirus vaccine development. VEEV rRT-PCR positives were detected in three mosquito pools from the Cx. Mel. vomerifer species trapped during the 2015 outbreak in El Real de Santamaria, Panama. Mosquitos from the Cx. Mel. vomerifer have been previously incriminated as a vector of VEEV in Panama [1]. Two

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

mosquito pools also yielded viral isolates, while one was only positive by rRT-PCR. None of the original pan-alphavirus convectional RT-PCRs were able to detect viral RNA in the mosquito pools. This suggests that the newly designed rRT-PCR has an increased sensitivity to detect VEEV viral RNA in mosquito vectors. No MADV infections in mosquito were detected during this investigation by either pan-alpha, rRT-PCR or isolation methods. The same pattern of lack of MADV isolation or detection in mosquitoes was observed during additional outbreak investigations undertaken by our group in Panama [29,30]. Interestingly, low MADV frequency of isolation was also observed during extensive mosquito investigations undertaken during the 1940-60s in Panama by the Gorgas Memorial Laboratory; in these occasions MADV was only isolated twice from Cx. Mel. taeniopus in 1964 and 1973, respectively [31,32]. Taken together, the early reports along with recent evidence suggest that mosquito vectors in Panama may be infected with MADV at a lower frequency when compared with VEEV. The reasons for this variation in MADV and VEEV frequency of isolation or detection from mosquitos are still unclear and may include variation in vector competence or viral heterologous competition. For the current study, we were able to demonstrate assay performance using a small set of human samples and mosquitos, but additional prospective testing is warranted to fully characterize the assays' clinical and surveillance performance. An additional limitation of this study is that the design requires two separate assays for three viruses. The optimal design targets for the VEE complex and MADV overlap in this highly conserved region. The two rRT-PCRs can be performed together on a single run, however, which improves lab workflow, and the VEE complex assay can be multiplexed with rRT-PCRs for other neurotropic arboviruses such as

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

West Nile and St. Louis encephalitis viruses without a loss in performance (manuscript in preparation). In summary, we describe novel VEE complex and MADV/EEEV rRT-PCRs that provide sensitive and specific detection while yielding significant benefits over available methods, allowing us to detect VEEV-MADV co-infection and VEEV human infection in samples that were negative with other techniques. Early acute samples (≤ 3 days since onset of symptoms), with coincidental VEEV specific antibodies and VEEV viral RNA suggest that VEEV reinfections are possible. In addition, our newly developed method also allows us to detect VEEV active viral circulation in mosquitos collected during an alphavirus outbreak response. The implementation of the assays in regions of endemicity may improve the identification and characterization of these neurotropic alphaviruses. Acknowledgements We thank Yaneth Pittí, Oriel Lezcano and Eddier Rivera and Mileika Santos for technical support with sample processing and mosquito classification and Alberto Cumbrera for the map construction. We also thank Kathryn Hanley for review and editions to the manuscript. **Funding Sources** JPC is funded by the Clarendon Scholarship from University of Oxford and Lincoln-Kingsgate Scholarship from Lincoln College, University of Oxford (grant number SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT, through the grants number FID-16-201 and FID-20-96 grant to JPC; the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant K08AI110528 to JJW) and Centers for Research in Emerging Infectious Diseases (CREID-CREATE-NEO) 1U01AI151807 grant awarded to NV by the National Institutes of Health (NIH); and by the Medical Research Council□São Paulo Research Foundation CADDE partnership award (MR/S0195/1 and FAPESP18/14389□0 to NRF) (https://caddecentre.org). NRF is supported by Wellcome Trust and Royal Society (Sir Henry Dale Fellowship. 204311/Z/16/Z).

References

- 411 1. Aguilar P v., Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC.
- Endemic Venezuelan Equine Encephalitis in the Americas: Hidden under the dengue umbrella. Future Virology. 2011. doi:10.2217/fvl.11.50
- Carrera J-P, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, et al. Eastern
 Equine Encephalitis in Latin America. New England Journal of Medicine. 2013.
 doi:10.1056/nejmoa1212628
- Vittor AY, Armien B, Gonzalez P, Carrera J-P, Dominguez C, Valderrama A, et al.
 Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan
 Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien,
 Panama. PLoS Neglected Tropical Diseases. 2016;10. doi:10.1371/journal.pntd.0004554
- 421 4. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, et al.
 422 Arboviral etiologies of acute febrile illnesses in western south America, 2000-2007. PLoS
 423 Neglected Tropical Diseases. 2010;4. doi:10.1371/journal.pntd.0000787
- 424 5. Aguilar P v., Greene IP, Coffey LL, Medina G, Moncayo AC, Anishchenko M, et al. 425 Endemic Venezuelan Equine Encephalitis in Northern Peru. Emerging Infectious 426 Diseases. 2004;10. doi:10.3201/eid1005.030634
- Carrera JP, Pittí Y, Molares-Martínez JC, Casal E, Pereyra-Elias R, Saenz L, et al.
 Clinical and serological findings of Madariaga and Venezuelan equine encephalitis viral
 infections: A follow-up study 5 years after an outbreak in Panama. Open Forum Infectious
 Diseases. 2020. doi:10.1093/ofid/ofaa359
- 431 7. Aguilar P v., Robich RM, Turell MJ, O'Guinn ML, Klein TA, Huaman A, et al. Endemic 432 Eastern Equine Encephalitis in the Amazon region of Peru. American Journal of Tropical 433 Medicine and Hygiene. 2007. doi:10.4269/ajtmh.2007.76.293
- 434 8. Arrigo NC, Adams AP, Weaver SC. Evolutionary Patterns of Eastern Equine Encephalitis 435 Virus in North versus South America Suggest Ecological Differences and Taxonomic 436 Revision. Journal of Virology. 2010. doi:10.1128/jvi.01586-09
- 437 9. Lednicky JA, White SK, Mavian CN, el Badry MA, Telisma T, Salemi M, et al.
 438 Emergence of Madariaga virus as a cause of acute febrile illness in children, Haiti, 2015 439 2016. PLoS Neglected Tropical Diseases. 2019. doi:10.1371/journal.pntd.0006972
- Pfeffer M, Proebster B, Kinney RM, Kaaden OR. Genus-specific detection of alphaviruses
 by a semi-nested reverse transcription-polymerase chain reaction. American Journal of
 Tropical Medicine and Hygiene. 1997;57. doi:10.4269/ajtmh.1997.57.709
- Brightwell G, Brown JM, Coates DM. Genetic targets for the detection and identification
 of Venezuelan equine encephalitis viruses. Archives of Virology. 1998;143.
 doi:10.1007/s007050050326
- 446 12. Romeiro MF, de Souza WM, Tolardo AL, Vieira LC, Henriques DA, de Araujo J, et al. A 447 real-time RT-PCR for rapid detection and quantification of mosquito-borne alphaviruses. 448 Archives of Virology. 2016;161. doi:10.1007/s00705-016-3019-0
- Linssen B, Kinney RM, Aguilar P, Russell KL, Watts DM, Kaaden OR, et al.
 Development of reverse transcription-PCR assays specific for detection of equine encephalitis viruses. Journal of Clinical Microbiology. 2000;38.
 doi:10.1128/jcm.38.4.1527-1535.2000
- Wang E, Paessler S, Aguilar P v., Carrara AS, Ni K, Greene IP, et al. Reverse transcription-PCR-enzyme-linked immunosorbent assay for rapid detection and

- differentiation of alphavirus infections. Journal of Clinical Microbiology. 2006;44. doi:10.1128/JCM.00175-06
- Pisano MB, Seco MPS, Ré VE, Farías AA, Contigiani MS, Tenorio A. Specific detection of all members of the Venezuelan Equine Encephalitis complex: Development of a RT-Nested PCR. Journal of Virological Methods. 2012;186.
 doi:10.1016/j.jviromet.2012.05.009
- 461 16. Sánchez-Seco MP, Rosario D, Quiroz E, Guzmán G, Tenorio A. A generic nested-RT 462 PCR followed by sequencing for detection and identification of members of the alphavirus genus. Journal of Virological Methods. 2001. doi:10.1016/S0166-0934(01)00306-8
- Bronzoni RVM, Moreli ML, Cruz ACR, Figueiredo LTM. Multiplex nested PCR for
 Brazilian Alphavirus diagnosis. Transactions of the Royal Society of Tropical Medicine
 and Hygiene. 2004;98. doi:10.1016/j.trstmh.2003.09.002
- Vina-Rodriguez A, Eiden M, Keller M, Hinrichs W, Groschup MH. A quantitative realtime RT-PCR assay for the detection of venezuelan equine encephalitis virus utilizing a universal alphavirus control RNA. BioMed Research International. 2016;2016. doi:10.1155/2016/8543204
- 471 19. Claudino-Sales V. Darien National Park, Panama. Coastal Research Library. 2019. doi:10.1007/978-94-024-1528-5_10
- Carrera JP, Bagamian KH, Travassos Da Rosa AP, Wang E, Beltran D, Gundaker ND, et
 Human and equine infection with alphaviruses and flaviviruses in panamá during 2010:
 A Cross-Sectional study of household contacts during an encephalitis outbreak. American
 Journal of Tropical Medicine and Hygiene. 2018. doi:10.4269/ajtmh.17-0679
- Sallum MAM, Forattini OP. Revision of the spissipes section of culex (melanoconion)
 (diptera: Culicidae). Journal of the American Mosquito Control Association. 1996.
- 479 22. Johnson BW, Kosoy O, Wang E, Delorey M, Russell B, Bowen RA, et al. Use of
 480 Sindbis/eastern equine encephalitis chimeric viruses in plaque reduction neutralization
 481 tests for arboviral disease diagnostics. Clinical and Vaccine Immunology. 2011;18.
 482 doi:10.1128/CVI.05129-11
- Quiroz E, Aguilar P v., Cisneros J, Tesh RB, Weaver SC. Venezuelan equine encephalitis
 in Panama: Fatal endemic disease and genetic diversity of etiologic viral strains. PLoS
 Neglected Tropical Diseases. 2009. doi:10.1371/journal.pntd.0000472
- Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, et al.
 GenBank. Nucleic Acids Research. 2018. doi:10.1093/nar/gkx1094
- Fitzgibbon JE, Sagripanti JL. Simultaneous identification of orthopoxviruses and alphaviruses by oligonucleotide macroarray with special emphasis on detection of variola and Venezuelan equine encephalitis viruses. Journal of Virological Methods. 2006;131. doi:10.1016/j.jviromet.2005.08.007
- 492 26. Relova D, Rios L, Acevedo AM, Coronado L, Perera CL, Pérez LJ. Impact of RNA 493 degradation on viral diagnosis: An understated but essential step for the successful 494 establishment of a diagnosis network. Veterinary Sciences. 2018;5. 495 doi:10.3390/vetsci5010019
- 496 27. Luciani K, Abadía I, Martínez-Torres AO, Cisneros J, Guerra I, García M, et al. Case 497 report: Madariaga virus infection associated with a case of acute disseminated 498 encephalomyelitis. American Journal of Tropical Medicine and Hygiene. 2015;92.

499 doi:10.4269/ajtmh.14-0845

- 500 28. Torres-ruesta A, Chee RSL, Ng LFP. Insights into antibody-mediated alphavirus 501 immunity and vaccine development landscape. Microorganisms. 2021. 502 doi:10.3390/microorganisms9050899
- Torres R, Samudio R, Carrera JP, Young J, Maârquez R, Hurtado L, et al. Enzootic
 mosquito vector species at equine encephalitis transmission foci in the República de
 Panama. PLoS ONE. 2017. doi:10.1371/journal.pone.0185491
- 506 30. Carrera J-P, Cucunuba ZM, Neira K, Lambert B, Pitti Y, Liscano J, et al. Endemic and epidemic human alphavirus infections in eastern Panama: An analysis of population-based cross-sectional surveys. American Journal of Tropical Medicine and Hygiene. 2020;10: 901462. doi:10.4269/ajtmh.20-0408
- 510 31. Dietz WH, Galindo P, Johnson KM, Galindo P, Dietz WH. Eastern equine 511 encephalomyelitis in Panama: The epidemiology of the 1973 epizootic. American Journal 512 of Tropical Medicine and Hygiene. 1980;29: 133–140. doi:10.4269/ajtmh.1980.29.133
- 513 32. Srihongse S, Galindo P. The isolation of eastern equine encephalitis virus from Culex (Melanoconion) taeniopus Dyar and Knab in Panama. Mosquito News . 1967;27: 74–76.
- 515 33. Esri inc. Esri World Topographic Map. ArcGIS Online. 2021.

517

518




Figure 1. Map with the distribution of VEEV human cases in Darien province, Panama.

Red dots represent the number of cases reported by locality. Map was created with ArcGIS

Desktop 10.6 using shapefiles from Esri. Data sources for the shapefiles include Esri, Garmin

International Inc., US Central Intelligence Agency, and National Geographic Society[33]




Figure 2. VEE and MADV/EEEV rRT-PCR linearity and limit of detection. A)

Amplification curves across the linear range of the VEE complex rRT-PCR with ssDNA (gray curves, subtype IAB) and RNA (pink dotted curves, subtype IC). **B**) Linearity and limit of detection for VEE were evaluated with ssDNA from subtypes IAB (grey) and IV (purple) and RNA from subtype IC (pink). (**C-D**) Linearity and limit of detection for MADV (C) and EEEV (D) were evaluated using ssDNA. For each virus, ssDNA was tested in quadruplicate at 8.0, 6.0, 4.0, 2.0 and 1.0 log₁₀ copies/μL (labelled a-e, respectively). 10-fold dilutions of VEEV subtype IC RNA were tested in duplicate starting at the highest concentration available (5.0 log₁₀ copies/μL). All data points are displayed, including 2/4 MADV and EEEV replicates that did not yield cycle threshold (Ct) values and were excluded from the linear regressions.

Table 1. Characteristics of clinical samples and laboratory results. Acute samples selected from the 2015 and 2017 Alphavirus outbreaks in Darien Province. Abbreviations: Ct, cycle threshold; neg, negative; pos, positive

RT-RT-**PCR PCR** rRT-PRNT-PRNT-**PCR** CtIgG-IgG-Days of IgM-IgM-Townsh Age Se **Sympto VEEV** MADV Code VEE MAD VEE MAD sympto Alph Alph valu ip \mathbf{x} m onset VEE \mathbf{V} \mathbf{v} \mathbf{V} \mathbf{V} ms es φ φ a (202 (201 \mathbf{V} 5) 1) 2583 Aug. El Real 0-9 0 pos M neg pos 29.3 neg neg neg neg <1:20 <1:20 84 2015 2677 July Cemaco 0-9 M 3 neg neg 37.8 neg neg neg <1:20 <1:20 pos pos 38 2017 2674 July F Tucuti 0-9 5 1:40 1:40 neg neg neg pos neg pos pos 11 2017 2583 Aug. 0-9 F El Real 1 <1:20 <1:20 pos neg neg neg neg neg neg 80 2015 2674 July 0-9 F 2 Yaviza <1:20 <1:20 pos pos neg neg neg neg neg 2017 10 2586 10-Sept. Yaviza M 0 pos 28 <1:20 <1:20 neg pos neg neg neg neg 57 19 2015 2585 20-Sept. F 2 Nicanor pos <1:20 <1:20 neg neg neg neg neg neg 35 29 2015 20-2584 La Aug. M 2 29 <1:20 <1:20 pos neg pos neg neg neg neg 01 Palma 29 2015 2583 30-Aug. 2 Metetí M 37 <1:20 <1:20 pos pos neg neg neg neg neg 95 39 2015 2583 30-Aug. 1 El Real M 26 <1:20 <1:20 pos neg pos neg neg neg neg 39 99 2015 2583 30-Aug. El Real M 2 pos 37 <1:20 <1:20 pos neg neg neg neg neg 85 39 2015 2583 30-Aug. 0 El Real M 27 <1:20 <1:20 neg neg neg neg pos pos pos 98 39 2015 2585 30-Sept. F 2 <1:20 Metetí <1:20 pos neg neg neg neg neg neg 39 36 2015 2583 30-Aug. El Real 5 M N/D N/D neg 34 neg neg neg pos pos neg 39 2015 86

31

neg

neg

neg

neg

<1:20

<1:20

El Real

 \geq

40 F

Aug.

2015

2

pos

neg

pos

2583

543

544

538

539540

541

^{*}Age categories in year s

φ Base on PRNT-80

Table 2. Species of mosquitos collected during the 2015 outbreak in El Real de Santa Maria, Panama.

Species	number	(%)	# Pools	VEEV- rRT- PCR	MADV- rRT- PCR	Isolates
Coquillettidia venezuelensis	490	37.5	29	0	0	0
Culex (Melanoconion) vomerifer	450	34.4	27	3	0	2
Culex (Melanoconion) pedroi	32	2.4	4	0	0	0
Aedes serratus	31	2.4	7	0	0	0
Aedes sp.	30	2.3	5	0	0	0
Culex (Melanoconion) sp.	30	2.3	6	0	0	0
Culex (Culex) interrogator	27	2.1	5	0	0	0
Anopheles trianulatus	23	1.8	2	0	0	0
Aedes eupoclamus	14	1.1	4	0	0	0
Culex (Culex) nigripalpus	14	1.1	3	0	0	0
Culex (Culex) sp.	14	1.0	4	0	0	0
Culex (Melanoconion) atratus	14	1.0	1	0	0	0
Culex (Melanoconion) adamesi	13	1.0	3	0	0	0
Others*	125	9.6	50	0	0	0
Total	1307	100	150	3	0	2

^{*} Species <1% abundance are listed as Others.

[#] Numbers of mosquito pools

Table 3. Primers and probes in the VEEV and MADV/EEEV rRT-PCRs.

Name	Jame Sequence ^a		Location (5'-3') ^c	Sequences Fully Matching ^d	
VEEV					
VEEV Forward 1	GAAAGTTCACGTTGAYATCGAGGA	200	44.67	156/159 (98)	
VEEV Forward 2	GAAGGTTCACGTTGAYATCGAGGA	200	44-67		
VEEV Reverse 1	GCTCTGGCRTTAGCATGGTC	200	144 162	159/159 (100)	
VEEV Reverse 2	GCTCTAGCRTTAGCATGGTC	200	144-163		
VEEV Probe	5'-FAM-TTGAGGTAGAAGCHAAGCAGGTC-BHQ-1-3'	400	112-134	158/159 (99)	
MADV/EEEV					
ME Forward	GAGATAGAAGCMACGCAGGTC	400	121-141; 99-119	31/32 (97); 1/449 (100)	
ME Reverse	TGYTTGGAATGCGTGTGC	400	255-272; 233-250	32/32 (100); 9/449 (98)	
MADV Probe	5'-FAM-CATCGAAAGCGAAGTGGACC-BHQ-1-3'	200	195-214	31/32 (97)	
EEEV Probe	5'-CFO560-TGAGGGAGAAGTGGAYACAGACC-BHQ-1-3'	400	176-198	6/449 (99)	
553					

Abbreviations: BHQ, black hole quencher; CFO560, CAL Fluor Orange 560; FAM, Fluorescein

552

554555

564

forward and reverse VEEV primers.

a probe sequences listed 5'-fluorophore-sequence-quencher-3'

^{557 &}lt;sup>b</sup> Concentration in the final reaction mixture

^c Location in the following complete genome sequences: VEEV strain VEEV/Homo sapiens/GTM/69Z1/1969/IAB

⁽Accession number KC344505.2); MADV strain Homo sapiens/Haiti-1901/2016 (MH359233.1); EEEV strain

⁵⁶⁰ EEEV/Culiseta melanura/USA/SL13-0764-C/2013 (Accession number KX029319.1)

⁵⁶¹ d Displayed as number of complete genome sequences without a mismatch in the primer/probe sequence over all complete genome sequences aligned (%). Genomes downloaded 22 Sept 2021. Data shown for the combination of